2021
Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations)
Mahdi H, Hafez N, Doroshow D, Sohal D, Keedy V, T. K, LoRusso P, Jürgensmeier J, Avedissian M, Sklar J, Glover C, Felicetti B, Dean E, Mortimer P, Shapiro GI, Eder JP. Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations). JCO Precision Oncology 2021, 5: 1432-1442. PMID: 34527850, PMCID: PMC8437220, DOI: 10.1200/po.20.00439.Peer-Reviewed Original ResearchConceptsHigh-grade serous ovarian cancerComplete responseResponse rateClinical benefit ratePartial response ratePrimary end pointOverall response rateHomologous recombination repair deficiencySerous ovarian cancerPoly (ADP-ribose) polymerase (PARP) inhibitorsPrior therapyUnacceptable toxicityEntire cohortRefractory cancerBenefit rateOvarian cancerPromising therapyPatientsBasket trialsDay 1End pointOlaparibPolymerase inhibitorsTherapyAdditional studies
1989
A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support.
Shea TC, Flaherty M, Elias A, Eder JP, Antman K, Begg C, Schnipper L, Frei E, Henner WD. A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support. Journal Of Clinical Oncology 1989, 7: 651-61. PMID: 2651580, DOI: 10.1200/jco.1989.7.5.651.Peer-Reviewed Original ResearchConceptsMaximum-tolerated doseAutologous bone marrow reinfusionAutologous bone marrow supportBone marrow reinfusionBone marrow supportMarrow reinfusionMarrow supportSystemic clearancePhase IConsiderable dose escalationRecurrent ovarian cancerPharmacokinetic studySevere ototoxicityToxicity consistingRenal dysfunctionDose escalationReversible hepatotoxicityContinuous infusionOvarian cancerActive drugHigh dosesLow dosesCarboplatinPatientsDoses